The effects of a humanized anti-IL-5 [interleukin 5] monoclonal antibody (SB-240563 [mepolizumab]) on asthma control, airway eosinophilia and the degree to which corticosteroid treatment can be reduced to maintain control.

Trial Profile

The effects of a humanized anti-IL-5 [interleukin 5] monoclonal antibody (SB-240563 [mepolizumab]) on asthma control, airway eosinophilia and the degree to which corticosteroid treatment can be reduced to maintain control.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma; Bronchitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2009 Results reported in New England Journal of Medicine.
    • 05 Mar 2009 Status changed from active, no longer recruiting to completed.
    • 30 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top